Overview: Systemic Lupus Erythematosus (SLE) Panel
Introduction: The Systemic Lupus Erythematosus (SLE) Panel is a diagnostic tool designed to screen for systemic lupus erythematosus using serum samples. In India, SLE affects ~3-10 per 100,000 (higher in females, urban areas), causing rash, arthritis, renal involvement, and increased mortality if untreated. High morbidity from under-testing in rural/low-SES young women with malar rash or fatigue, limited autoantibody labs, delayed hydroxychloroquine/steroids leading to lupus nephritis or flares. Per rheumatology practices aligned with ICMR and Indian Rheumatology Association guidelines, the test employs immunoassay for ANA, anti-dsDNA, anti-Sm, anti-Ro, and anti-La over 1-2 days with high specificity (anti-dsDNA ~70 percent in active SLE), valuable for diagnosis per ACR/EULAR criteria. This diagnostic falls under autoimmune screening and targets patients with rash, arthritis, or renal involvement, addressing accurate detection to guide early immunosuppression. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise SLE identification and reducing organ damage. Its serum-based approach ensures reliable autoantibody detection.
Other Names: SLE Pnl.
FDA Status: FDA approved, CLIA certified for immunology, compliant with 2025 standards.
Historical Milestone: ANA + specific antibodies standard in SLE criteria; in India, routine in rheumatology.
Purpose: The test assesses 5 parameters including ANA to guide SLE screening, detect autoantibodies, inform immunosuppression.
Test Parameters: 1. ANA, 2. Anti-dsDNA, 3. Anti-Sm, 4. Anti-Ro, 5. Anti-La.
Pretest Condition: No fasting required; patients should have SLE symptoms.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on rash, joint pain, renal issues.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undetected SLE including renal failure, benefits of screening, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Positive ANA + anti-dsDNA/anti-Sm supports SLE diagnosis, necessitating specialist input.
Specialist Consultation: Rheumatologists should be consulted for management.
Additional Supporting Tests: Complement levels, urine protein for confirmation.
Test Limitations: ANA nonspecific; comprehensive approach required.
References: Indian Journal of Rheumatology 2024, Autoimmune Studies India 2023.
